



09/03/04

1FW

PHA 4256.12 (3481/4)
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of Jaime L. Masferrer
Serial No. 10/827,075
Filed April 19, 2004
Confirmation No. 1885
For CARBONIC ANHYDRASE INHIBITOR

Art Unit 1614

September 2, 2004

COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VIRGINIA 22313-1450

SIR:

INFORMATION DISCLOSURE STATEMENT


* In accordance with 37 C.F.R. 1.97 and 1.98 and MPEP 609, and in compliance
with the duty of disclosure set forth in 37 C.F.R. 1.56, applicant submits copies of the
references listed on the attached PTO/SB/08A for consideration by the Patent and
Trademark Office in the above-entitled application and to be made of record therein.
In accordance with the OG notice of August 5, 2003 partially waiving the requirements
of 37 C.F.R. 1.98(a)(2)(i), copies of the U.S. patent documents are not supplied.
* Applicant submits herewith copies of the foreign patent documents and literature
references.

This Information Disclosure Statement is being submitted pursuant to 37 C.F.R.
§1.97(b) in that applicants believe that it is being filed prior to the mailing date of the
first Office action on the merits. Accordingly, neither a statement nor fee under 37
C.F.R. §1.97(c) or (d) is required. However, if an Office action was issued prior to the
date of mailing of this Information Disclosure Statement, the Commissioner is hereby
authorized to charge any required fees regarding this Information Disclosure Statement
to Deposit Account No. 19-1345.

Respectfully submitted,

Kathleen M. Petrillo, Reg. No. 35,076
SENNIGER POWERS
One Metropolitan Square, 16th Floor
St. Louis, Missouri 63102
(314) 231-5400

KPM/cms
Express Mail Label No. EV 504799616 US
Mail Stop Amendment

PTO/SB/08A			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) <div style="text-align: center;">  </div>			Application Number	10/827,075	
			Filing Date	April 19, 2004	
			Confirmation Number	1885	
			First Named Inventor	J. Masferrer	
			Group Art Unit	1614	
			Examiner Name		
Sheet	1	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Number	Kind Code ² (if known)		
	1	4,221,783	B1	Puscas et al.	09-09-1980
	2	5,095,026	B1	Schoenwald et al.	03-10-1992
	3	5,157,044	B1	Schoenwald et al.	10-20-1992
	4	5,416,091		King	05-16-1995
	5	5,466,823	B1	Talley et al.	11-14-1995
	6	5,547,975		Talley et al.	08-20-1996
	7	5,563,165		Talley et al.	10-08-1996
	8	5,633,272	B1	Talley et al.	05-27-1997
	9	5,635,172	A	Jani et al.	06/03/1997
	10	5,691,375	B1	Behounek et al.	11-25-1997
	11	5,760,068	B1	Talley et al.	06-02-1998
	12	5,944,021	B1	Rodriguez	08-31-1999
	13	5,972,684	A	Bandman et al.	10/26/1999
	14	5,972,986	A	Seibert et al.	10/26/1999
	15	6,025,353	B1	Masferrer et al.	02-15-2000

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

	16	6,090,834		Talley et al.	07-18-2000
	17	6,448,030		Rust et al.	09-10-2002
	18	6,465,448		Gerson et al.	10-15-2002
	19	6,664,288		Pardee et al.	12-16-2003
	20	2002/0006915		Mack Strong et al.	01-17-2002
	21	2002/0035264	A1	Kararli et al.	03-21-2002

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office	Number ⁴	Kind Code ² (if known)			
	22	CA	2372912	A	G.D. Searle & Co.	04-23-1998	
	23	DE	19600721	A	Hoechst AG	07-17-1997	
	24	EP	0826676	A1	Japan Tobacco Inc.	03-04-1998	
	25	EP	0 826 676	A1	Japan Tobacco Inc.	03/04/1999	
	26	WO	95/15316	A1	G.D. Searle & Co.	06-08-1995	
	27	WO	96/19462	A1	Japan Tobacco Inc. et al.	06-27-1996	A
	28	WO	96/25405	A1	G.D. Searle & Co.	08-22-1996	
	29	WO	97/30704	A2	Merck & Co., Inc., et al.	08-28-1997	
	30	WO	97/38986	A1	G.D. Searle & Co.	10-23-1997	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	3	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

	31	WO	99/40867	A1	Rodriguez	08-19-1999	
	32	WO	00/08024	A	Laboratorios S.A.L.V.A.T.	02-17-2000	
	33	WO	00/18741	A	Fuji-Sawa Pharmaceutical Co. Ltd.	04-06-2000	
	34	WO	00/23433	A	G.D. Searle & Co.	04-27-2000	
	35	WO	00/25771	A	Synphora AB	05-11-2000	
	36	WO	00/32189	A1	G.D. Searle & Co.	06-08-2000	
	37	WO	01/28548	A1	Texas Heart Institute	04-26-2001	
	38	WO	01/49675	A	Pharmacia Corporation	07-12-2001	
	39	WO	01/57015	A1	Cayman Chemical Company, Inc.	08-09-2001	
	40	WO	01/90086	A1	Japan Tobacco Inc.	11-29-2001	
	41	WO	01/91856	A2	Pharmacia Corporation	12-06-2001	
	42	WO	02/05815	A1	Pharmacia & Upjohn Company	01-24-2002	
	43	WO	02/05848	A2	Pharmacia Corporation	01-24-2002	
	44	WO	02/07731	A2	Sucampo AG	01-31-2002	
	45	WO	02/13800	A2	Stefansson	02-21-2002	
	46	WO	02/40052	A1	AGA AB	05-23-2002	
	47	WO	03/013655	A2	Pharmacia Corporation	02-20-2003	
OTHER ART - NON PATENT LITERATURE DOCUMENTS							

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	4	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ⁶
	48	BRADWELL, A.R., et al., "Methazolamide Treatment of Acute Mountain Sickness," Clinical Science (London), Vol. 79, No. Supp. 23, 1990, pg. 9P, Summer Meeting of the Medical Research Society, Warwick, England, UK, July 5-6, 1990, XP008025380	
	49	BROOKS, D.P., et al., "Renal effects of cyclooxygenase inhibitors in volume-depleted dogs", Inflammapharmacology (2000), pp. 69-79, Vol. 8, No. 1	
	50	CARLSEN, J., et al., "Nephrolithiasis with Dorzolamide", Archives of Ophthalmology, Aug. 1999, pp. 1087-1088, Vol. 117, No. 8, XP008025376	
	51	CHEGWIDDEN et al., "Sulphonamide inhibitors of carbonic anhydrase inhibit the growth of human lymphoma cells in culture", Inflammopharmacology, 1995, 3(3): 231-239, XP008020859	
	52	DALKALAS, M.C., et al., "Treatment of "Permanent" Muscle Weakness in Hypokalemic Periodic Paralysis", Neurology, April 1980, pp. 379-380, Vol. 30, No. 4, 32nd Annual Meeting of the American Academy of Neurology, New Orleans, LA, USA, May-1-3, 1980, XP008025374	
	53	DALKALAS, M.C., et al., "Treatment of "Permanent" Muscle Weakness in Familial Hypokalemic Periodic Paralysis", Muscle & Nerve, Mar/Apr. 1983, pp. 182-186, Vol. 6, No. 3, XP008025373	
	54	Database, WPI, Section Ch, Week 200025, Derwent Publications Ltd., London, GB; Class B03, AN 2000-293087, XP002251841 & WO 0018741A, Fujisawa Pharm Co Ltd, April 6, 2000, Abstract	
	55	ELLIS, P.P., "Urinary Calculi With Methazolamide Therapy", Documenta Ophthalmologica, 1973, pp. 137-142, Vol. 34, No. 2, XP008025381	
	56	FOSSLIEN, E, "Biochemistry of Cyclooxygenase(COX)-2 Inhibitors and Molecular Pathology of COX-2 in Neoplasia", Critical Reviews in Clinical Laboratory Sciences, 2000, 37(5): 431-502, XP008020865	
	57	GRÜNEBERG et al., "Successful virtual screening for novel inhibitors of human carbonic anhydrase: strategy and experimental confirmation", Journal of Medicinal Chem., 2002, V45, 17: 3588-3602	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	5	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

	58	GRÜNEBERG et al., "Subnanomolar Inhibitors from Computer Screening: A Model Study Using Human Carbonic Anhydrase II", Angew. Chem. Int. Ed., 2001, pp. 389-393, Vol. 40, No. 2	
	59	International Search Report for application no. PCT/US/03/04469, dated September 5, 2003	
	60	International Search Report for application no. PCT/US03/04494, dated September 29, 2003	
	61	International Search Report for application no. PCT/US/03/04494, dated January 14, 2004	
	62	IVANOV et al. "Down-regulation of Transmembrane Carbonic Anhydrases in Renal Cell Carcinoma Cell Lines by Wild-Type von Hippel-Lindau Transgenes", Proc. Natl. Acad. Sci. USA, 1998, pp. 12596-12601, Vol. 95.	
	63	KALUZ et al., "Transcriptional Regulation of the MN/CA 9 Gene Coding for the Tumor-Associated Carbonic Anhydrase IX", The Journal of Biological Chemistry, 1999, pp. 32588-32595, Vol. 274, No. 46.	
	64	KASAI et al., "Potentiation of Antitumor Activity of 1-phthalidyl 5-fluorouracil by Acetazolamide", Cancer Chemother Pharmacol, 1986, pp. 55-57, Vol 16.	
	65	KIVELÄ et al., "Expression of a Novel Transmembrane Carbonic Anhydrase Isozyme XII in Normal Human Gut and Colorectal Tumors", American Journal of Pathology, 2000, pp. 577-584, Vol. 156, No. 2.	
	66	MASFERRER et al., "Antiangiogenic and Antitumor Activities of Cyclooxygenase-2 Inhibitors" Cancer Research, 2000, pp. 1306-1311, Vol. 60.	
	67	MATSUSHITA, M., et al., "Pharmacological profile of JTE-522, a novel prostaglandin H synthase-2 inhibitor, in rats, Inflammation Research", 1997, pp. 461-466, Vol. 46, No. 11, XP001176824	
	68	McKIERNAN et al., "The Detection of Renal Carcinoma Cells in the Peripheral Blood with an Enhanced Reverse Transcriptase-Polymerase Chain Reaction Assay for MN/CA9", Cancer, 1999, pp. 492-497, Vol. 86, No. 3.	
	69	MUDGE GH, "Diuretics and other agents employed in the mobilization of edema fluid", Gilman, A.G., L.S. Goodman and A. Gilman, 1980, 892-915, XP008009981	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	6	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

	70	MURAKAMI et al., "MN/CA9 Gene Expression as a Potential Biomarker in Renal Cell Carcinoma." BJU Interantional, 1999, pp. 743-747, Vol. 83.	
	71	NÓGRÁDI et al., "The Role of Carbonic Anhydrases in Tumors", American Journal of Pathology, 1998, pp. 1-4, Vol. 153, No. 1.	
	72	OWA et al., "Novel Sulphonamide Derivatives for the Treatment of Cancer", Exp. Opin. Ther. Patents, 2000, pp. 1725-1740, Vol. 10, No. 11.	
	73	PARFITT et al., "Martindale, The Complete Drug Reference", Pharmaceutical Press, 1999, XP002252808	
	74	PARFITT, K., "Martindale, The Complete Drug Reference, 32nd Edition", 1999, p. 778, PHARMACEUTICAL PRESS, London, UK, XP002264621	
	75	PARKKILA et al., "Carbonic Anhydrase Inhibitor Suppresses Invasion of Renal Cancer Cells in vitro", PNAS, 2000, pp. 2220-2224, Vol. 97, No. 5.	
	76	PASTOREKOVÁ et al., "A Novel Quasi-viral Agent, MaTu, Is a Two-Component System", Virology, 1992, pp. 620-626, Vol. 187.	
	77	PENNING, T.D., et al., "Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors: Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib)", Journal of Medicinal Chemistry, 1997, pp. 1347-1365, Vol. 40, No. 9, XP002114833	
	78	PORCELLI, M.J., et al., "A trek to the top: A review of acute mountain sickness", Journal of the American Osteopathic Association, 1995, pp. 718-720, Vol. 95, No. 12, XP000886754	
	79	PUSCAS et al., "The Carbonic Anhydrase Activation is Involved in the Chemopreventive, Antitumor Effects of Non-Steroidal Anti-Inflammatory Drugs", Experimental Oncology, 1999, pp. 121-126, Vol. 21.	
	80	PUSCAS et al., "Nonsteroidal Anti-Inflammatory Drugs Activate Carbonic Anhydrase by a Direct Mechanism of Action", The Journal of Pharmacology and Experimental Therapeutics, 1996, pp. 1464-1466, Vol. 277, No. 3.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	7	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

81	RITSCHER, W.A., et al., "Pharmacokinetics of Acetazolamide in Healthy Volunteers after Short- and Long-Term exposure to High Altitude", Journal of Clinical Pharmacology, June 1998, pp. 533-539, Vol. 38, No. 6, XP008025379	
82	SAARNIO et al., "Immunohistochemical Study of Colorectal Tumors for Expression of a Novel Transmembrane Carbonic Anhydrase, MN/CA IX, with Potential Value as a Marker of Cell Proliferation", American Journal of Pathology, 1998, pp. 279-285, Vol. 153, No. 1.	
83	SCOZZAFAVA et al., "Carbonic Anhydrase Inhibitors: Synthesis of N-Morpholyl-thiocarbonylsulfonylamino Aromatic/Heterocyclic Sulfonamides and their Interaction with Isozymes I, II, and IV", Bioorganic & Medicinal Chemistry Letters, 2000, pp. 1117-1120, Vol. 10.	
84	SCOZZAFAVA et al., "Carbonic Anhydrase and Matrix Metalloproteinase Inhibitors: Sulfonylated Amino Acid Hydroxamates with MMP Inhibitory Properties Act as Efficient Inhibitors of CA Isozymes I, II, and IV, and N-Hydroxysulfonamides Inhibit both these Zinc Enzymes", Journal of Medicinal Chemistry, 2000, pp. 3677-3687, Vol. 43.	
85	SUPURAN et al. "Carbonic Anhydrase Inhibitors - Part 94. 1,3,4-Thiadiazole-2-Sulfonamide Derivatives as Antitumor Agents?", Eur. J. Med. Chem, 2000, pp. 867-874, Vol. 35.	
86	TAWIL, R., et al., "Acetazolamide-induced nephrolithiasis: Implications for treatment of neuromuscular disorders", Neurology, June 1993, pp. 1105-1106, Vol. 43, No. 6, XP008025375	
87	TAWIL, R., et al., "Randomized Trials of Dichlorphenamide in the Periodic Paralysis", Annals of Neurology, Jan. 2000, pp. 46-53, Vol. 47, No. 1, XP008025370	
88	TEICHER et al., "A Carbonic Anhydrase Inhibitor as a Potential Modulator of Cancer Therapies", Anticancer Research, 1993, pp. 1549-1556, Vol. 13	
89	TRICARICO, D., et al., "Effects of acetazolamide on Ca ²⁺ activated K ⁺ channels of skeletal muscle fibers of K ⁺ depleted rats, an animal model of hypokalemic periodic paralysis", Society for Neuroscience Abstracts, 1997, p. 1482, Vol. 23, No. 1-2, 27th Annual Meeting of the Society for Neuroscience; New Orleans, LA, USA, Oct. 25-30, 1997, XP001160974,	
90	TÜRECI et al., "Human Carbonic Anhydrase XII: cDNA Cloning, Expression, and Chromosomal Localization of a Carbonic Anhydrase Gene that is Overexpressed in Some Renal Cell Cancers", Proc. Natl. Acad. Sci. USA, 1998, pp. 7608-7613, Vol. 95.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

PTO/SB/08A INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/827,075
				Filing Date	April 19, 2004
				Confirmation Number	1885
				First Named Inventor	J. Masferrer
				Group Art Unit	1614
				Examiner Name	
Sheet	8	of	8	Attorney Docket No.	PHA 4256.12(3481/4)

	91	ULMASOV et al., "Purification and Kinetic Analysis of Recombinant CA XII, a Membrane Carbonic Anhydrase Overexpressed in Certain Cancers", PNAS, 2000, pp. 14212-14217, Vol. 97, No. 26.	
	92	VERMYLEN et al. "Carbonic Anhydrase IX Antigen Differentiates Between Preneoplastic Malignant Lesions in Non-Small Cell Lung Carcinoma", Eur Respir J., 1999, pp. 806-811, Vol. 14.	
	93	WAKITANI, K., et al., "JTE-552 Selectively inhibits cyclooxygenase-2-derived prostaglandin production in inflammatory tissues", Inflammation Research (2000), pp. 117-122, Vol. 49, No. 3, XP001126211	
	94	WILGUS, T.A., et al., "Topical application of a selective cyclooxygenase inhibitor suppresses UVB Vol. 62, No. 4, mediated cutaneous inflammation", Prostaglandins & Other Lipid Mediators, (2000), pp. 367-384, XP001074004,	
	95	WOLFENSBERGER, T., "The Role of Carbonic Anhydrase Inhibitors in the Management of Macular Edema", Documenta Ophthalmologica, 1999, pp. 387-397, Vol. 97.	
	96	WYKOFF et al., "Hypoxia-inducible Expression of Tumor-Associated Carbonic Anhydrases", Cancer Research, 2000, pp. 7075-7083, Vol. 60.	
	97	YOUSSEF et al., "Synthesis of certain diarylsulfonylureas as antitumor agents", Medicinal Chemistry Research, 2001, 10(6): 404-418, XP008020857	
	98	ZÁVADA et al., "Human Tumor-Associated Cell Adhesion Protein MN/CA IX: Identification of M75 Epitope and of the Region Mediating Cell Adhesion", British Journal of Cancer, 2000, pp. 1808-1813, Vol. 82, No. 11.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached or place an "A" here if English language abstract is attached..

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.